SubHero Banner
Text

Sutent® (sunitinib malate) – New indication

November 16, 2017 – The FDA announced the approval of Sutent (sunitinib malate) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

Download PDF